About Us

Tablets packages

Our Goal

We are developing first-in-class, daily tablet protein and peptide replacement therapies, designed for patients to live healthier and injection-free, as they manage their chronic diseases. Our goal is for our small, oral protein tablets to change treatment outcomes for patients globally.

Our lead program is potentially the first oral osteoanabolic (bone forming) daily tablet to treat osteoporosis – a disease that disproportionately affects women and where current bone forming agents are only available in injectable formats.

We aspire to continue to validate our platform across a plethora of additional high value therapeutic proteins via our internal efforts and in collaboration with leading protein therapeutic companies.

Scientific Advisory Board

Professor John P. Bilezikian

Vice-Chair, Department of Medicine for International Research and Education; Chief, Emeritus, of the Division of Endocrinology; Director, Emeritus, of the Metabolic Bone Diseases Program at Columbia University Medical Center

Professor Maria Luisa Brandi

Professor of Endocrinology, FIRMO Foundation, Florence, Italy

Professor Bart Clarke

Professor of Medicine and Consultant, Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic

Professor Felicia Cosman

Professor of Medicine, Emerita, Columbia University College of Physicians and Surgeons, Division of Endocrinology; Co-Editor in Chief of the journal Osteoporosis International

Professor William Fraser

Professor of Medicine and Deputy Head of Norwich Medical School at the University of East Anglia and Consultant in Metabolic Medicine at the Norfolk and Norwich University Hospital, UK

Dr. Roger Garceau

Former Chief Medical Officer and EVP at NPS Pharmaceuticals and Shire plc (Natpara®); with previous senior management roles at Sanofi Aventis and Pharmacia

Professor Sofia Ish-Shalom

Vice President of the Israeli Foundation for Osteoporosis and Bone Diseases (IFOB), Endocrine Clinic Elisha Hospital; prior Head of Bone and Mineral Metabolism Unit, Rambam Health Care Campus, Haifa Israel

Professor Socrates Papapoulos

Emeritus Professor in Diseases of Bone & Mineral Metabolism, Advisor Center for Bone Quality, Leiden University Medical Center, The Netherlands

Professor Steven R. Goldstein

Professor of Obstetrics and Gynecology at New York University School of Medicine and former President of The International Menopause Society, the North American Menopause Society.

Miranda Toledano

Chief Executive Officer

Ms. Toledano has over 20 years of C-level leadership, principal investment and Wall Street/ capital market experience in the biotech sector. Since 2018, Ms. Toledano served as a Member of the Board, Chair of the Audit Committee, and Member of the Compensation and Scientific Advisory Committee at Entera, and as CEO since July 2022. Previously, Miranda served as COO and CFO, and Director of TRIGR Therapeutics, a private oncology focused, clinical stage bispecific antibody company acquired by Compass Therapeutics (Nasdaq: CMPX) in June 2021. At TRIGR, Miranda oversaw the clinical development of lead asset TR009 (now CTX-009) and led strategic execution, including a $117 million China License Transaction and 

acquisition by CMPX 3 years after the Company’s founding. From 2012 to 2016, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed biotech equity financings (IPOs, ATMs, and follow-ons) totaling over $4 billion in aggregate value. Earlier in her career, Ms. Toledano served as vice president in the investment group of Royalty Pharma (Nasdaq: RPRX). Ms. Toledano is also a Director at Journey Medical (Nasdaq: DERM) and NEXGEL (Nasdaq: NXGL). Ms. Toledano holds a B.A. in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.

Art Santora, MD, PhD

Chief Medical Officer

Dr. Arthur Santora has served as our Chief Medical Officer since September 2018. Dr. Santora has more than 30 years of experience in the biopharmaceutical industry. He spent the majority of his career in the clinical research team at Merck & Co., Inc., from June 1989 to March 2017, where he was the lead clinical research physician responsible for much of the clinical development of Fosamax® (alendronate sodium), one of the world’s most prescribed osteoporosis treatments. He was closely involved in the clinical development of Merck’s once-weekly Fosamax Plus D (alendronate sodium/ vitamin D3 combination tablets), the first drug/vitamin combination tablet in the US. His position at Merck immediately prior to his termination of services in 2017 was Scientific Associate Vice President of Clinical Research, where he was

directly responsible for the technical and scientific support for all clinical research of Fosamax/Fosamax plus D and contributed to the development of many other osteoporosis and endocrine marketed and investigational drugs. Prior to joining Merck, he served as a Medical Officer at the US FDA and subsequently was a faculty member at Wayne State University Medical School in Detroit. Dr. Santora is a Clinical Associate Professor at the clinical faculty of Rutgers Robert Wood Johnson Medical School in New Brunswick, New Jersey. He has graduate training in Internal Medicine at Emory, and its Endocrinology and Metabolism subspecialty at the NIH in Bethesda. Dr. Santora received his M.D. and Ph.D. in biochemistry from Emory University in Atlanta.

Hillel Galitzer, PhD

Chief Operating Officer

Dr. Hillel Galitzer has served as our Chief Operating Officer since February 2014, prior to which he served as our Director of Scientific Development from July 2012. Dr. Galitzer has more than ten years of experience in medical research and molecular biology. Between August 2010 and February 2014, Dr. Galitzer was an analyst and the chief operating officer for Hadasit Bio Holdings Ltd., a publicly traded company on the Tel Aviv Stock Exchange (TASE: HDST) and OTC markets. He is the co-founder and former chief operating officer of 

Optivasive Inc. He has written numerous publications in peer-reviewed journals and has lectured and presented in international conferences and universities. Dr. Galitzer received his Ph.D. from the Hebrew University Medical School in Jerusalem, where he was mentored by two world renowned researchers in the areas of parathyroid hormone and calcium regulation, his M.B.A. from Bar Ilan University in Israel and his B.Med.Sc. from the Hebrew University Medical School in Jerusalem.

Gregory Burshtein, PhD

VP of Research & Development

Dr. Gregory Burshtein has served as our Vice President of Research and Development since January 2016, prior to which he served as our Director of Pharmaceutical Research and Development from September 2012. Dr. Burshtein has more than 15 years of experience in pharmaceutical and biopharmaceutical research focusing on advanced oral drug delivery, protein based oral drug delivery and oral delivery of biologic molecules. He has written several publications 

in peer-reviewed journals and has presented in numerous international conferences. Dr. Burshtein is the author of more than 10 patents and patent applications in the field of drug delivery. Dr. Burshtein received his Ph.D. in Pharmaceutical Sciences, MSc in Clinical Pharmacy and B. Pharm from the Institute for Drug Research, School of Pharmacy, Faculty of Medicine of the Hebrew University of Jerusalem.

Anke Hoppe

VP of Clinical Operations

Ms. Hoppe leads clinical operations at Entera since 2018. Ms. Hope has over 30 years of clinical operations experience in major international pharmaceutical and biopharmaceutical companies and various clinical research organizations. 

Her experience ranges from serving as clinical research associate (Sanofi for 9 years) to project management lead at several of the leading CROs and Vertex Pharmaceuticals.

Dana Yaacov, CPA

Chief Financial Officer

Dana Yaacov-Garbeli has served as our Israel-based Chief Financial Officer since June 2019 and as the Company’s Chief Financial Officer effective as of July 15, 2022. Ms. Yaacov-Garbeli has over 15 years of chief finance and accounting experience. She previously served as Senior Manager at PwC Israel overseeing audits of public and private companies. She is an expert in financial planning, operations management, external and internal audit for 

public multinational companies under US GAAP, IFRS and PCAOB standards. Ms. Yaacov-Garbeli is also a partner at A2Z-Finance, a company that provides financial and accounting services. Ms. Yaacov-Garbeli holds a B.A in accounting and business management and an MBA in financial management from The College of Management and Academic studies. Ms. Yaacov-Garbeli is a Certified Public Accountant in Israel.

Mr. Gerald Lieberman

Chairman of the Board

Gerald Lieberman has served as a member of our Board since April 2014 and became our Chairman in July 2019. Mr. Lieberman is also a member of the board of directors of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global leader in pharmaceuticals and the world’s largest generic drug developer and manufacturer, where he chairs the Audit Committee and serves on both the Human Resources and Compensation Committee and the Finance Committee. He also serves as Chairman of the Board of Directors of DosenRx, Ltd., a Digital health company that has developed a personalized, patient-controlled device for delivering medication. He is also currently a special advisor at Reverence Capital Partners, a private investment firm focused on the middle-market financial services industry. From 2000 to 2009, Mr. Lieberman was an executive at Alliance Bernstein L.P., where he 

served as President and Chief Operating Officer from 2004 to 2009, as Chief Operating Officer from 2003 to 2004 and as  Executive Vice President, Finance and Operations from 2000 to 2003. From 1998 to 2000, he served as Senior Vice President, Finance and Administration at Sanford C. Bernstein & Co., Inc., until it was acquired by Alliance Capital in 2000, forming Alliance Bernstein L.P. Prior to that, he served in various executive positions at Fidelity Investments and at Citicorp. Prior to joining Citicorp he was a certified public accountant with Arthur Andersen. He previously served on the board of directors of Forest Laboratories, LLC from 2011 to 2014, Computershare Ltd. from 2010 to 2012 and Alliance Bernstein L.P. from 2004 to 2009. Mr. Lieberman received a B.S. Beta Gamma Sigma with honors in business from the University of Connecticut.

Dr. Roger Garceau

Dr. Roger J. Garceau has served as a member of our Board since March 2016 and as our interim CEO From August 2020 to January 4, 2021. Dr. Garceau served also served as our Chief Development Advisor since December 2016 and until December 2021 (excluding the period he served as our interim CEO).. Dr. Garceau has more than 30 years of broad pharmaceutical industry experience. He has been a director of Enterome SA since December 2016, and a director of ArTara Therapeutics since January 2019. Prior to joining Entera, Dr. Garceau served as Chief Medical Officer and Executive Vice President of NPS Pharmaceuticals, Inc. since December

2008 and January 2013 respectively, until February 2015, when NPS Pharmaceuticals, Inc., then traded on Nasdaq, was acquired by Shire plc. (NASDAQ: SHPG). Previously, Dr. Garceau served in several managerial positions with Sanofi-Aventis (NYSE: SNY) from 2002 until 2008, and Pharmacia Corporation from 1986 until 2002. Dr. Garceau is a board-certified pediatrician and is a Fellow of the American Academy of Pediatrics. Dr. Garceau holds a B.S. in Biology from Fairfield University in Fairfield, Connecticut and an M.D. from the University of Massachusetts Medical School. 

Sean Ellis

Sean Ellis has served as a member of our Board since June 2019. Mr. Ellis brings extensive knowledge of both life sciences and the U.S. financial markets, with a longstanding history in asset management. Mr. Ellis is a fund manager of Centillion Fund, a venture capital fund dedicated to Israeli investments, with a 


primary focus on investments in the biotech and related healthcare industries. Centillion is one of Entera Bio’s earliest investors and largest shareholders. He holds a BA from New York University and MBA from Columbia University.

Haya Taitel

Ms. Taitel has over 30 years of global C-level biopharma commercial and strategic executive experience.  Ms. Taitel currently serves as the Head of Sanofi’s Global Transplant Franchise where she is responsible for increasing franchise growth and profitability. Prior to her role at Sanofi, Ms. Taitel served as the Chief Commercial Officer of Kadmon Pharmaceuticals, LLC, where she contributed to the launch of Rezurock®, from 2013 until the company was acquired by Sanofi for $1.9 billion in November 2021. Ms. Taitel also led 

Kadmon Board’s Executive Commercial  Committee. Beginning in 1997, Ms. Taitel had held various  commercial leadership positions of increasing seniority at Johnson and Johnson in multiple therapeutic areas, including oncology, immunology, neurology and women’s healthcare. Ms. Taitel holds a Master of Science, Pharmacology, (PharmD equivalence) from Temple University and a Bachelor of Science, Pharmacy and Biology from the Hebrew University School of Pharmacy in Jerusalem, Israel.

Mr. Yonatan Malca

Yonatan Malca has served as a member of our Board since 2011. Mr. Malca currently serves as a Chief Executive Officer and director of NanoGohst Ltd. Since 2010 until 2021, he served as a Chief Executive Officer and director of D.N.A Biomedical Mr. Malca also serves as a director of Nextgen-Biomed LTD. (TASE: 

NXGN) and Jungo Connectivity Ltd.(TASE: JNGO) , each of which is an Israeli public  company. Mr. Malca holds a B.A. in Economics and Statistics from Bar-Ilan University and an M.A. in Economics and Finance from Bar Ilan University, Israel.

Mr. Gerald M. Ostrov

Gerald M. Ostrov has served as a member of our Board since January 2019. Mr. Ostrov consults and invests in new technologies in the medical device and consumer products fields. Mr. Ostrov currently serves on the board of directors of several privately held companies, including Mother’s Choice, a natural products company working with industry giants, Addon Optics, an innovative technology company, and Nuvo, a developer of next generation baby and mother health monitoring for both hospital and home use. From 2008 to 2010, he served as Chairman and CEO of Bausch & Lomb. There Mr. Ostrov led the stabilization, streamlining and pipeline building of Bausch & Lomb following its going-private transaction.

From 1998 until 2006, Mr. Ostrov very successfully served as Company Group Chairman for Johnson & Johnson’s Worldwide Vision Care businesses. From 1991 to 1998, Mr. Ostrov worked for Johnson & Johnson and quickly rose to serve as Company Group Chairman of the Consumer and Personal Care businesses in North America. From 1982 to 1991, he served as President of CIBA Consumer Pharmaceuticals Company. From 1976 to 1982, he worked for the Health Care Division of Johnson & Johnson. From 1973 to 1976, Mr. Ostrov worked at Procter & Gamble. Mr. Ostrov holds a B.S. from Cornell and an M.B.A. from Harvard.

Mr. Ron Mayron

Ron Mayron has served as a member of our Board since April 2021 and is a global healthcare specialist who serves on the boards of numerous public and privately held pharma and medical device companies in Israel, including DNA BioMedical Solutions, Innocan Pharma, and IceCure Medical. His prior executive experience includes several leadership positions culminating in CEO of Teva Israel & Africa from 2009 until 2013 and 

CEO of S.L.E from 1999 and until 2007. His expertise within healthcare includes M&A, integration and implementation, global business development, global operations, and supply chain management. He earned a B.Sc. from Ben-Gurion University, and an MBA from the University of Tel Aviv, and attended several programs at Insead University Fontainebleu, France and the Massachusetts Institute of Technology, Boston.

Thank You

Message Sent!

We will get back to you soon